{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Darbepoetin+Alfa", "query": { "intervention": "Darbepoetin Alfa" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 61, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Darbepoetin+Alfa&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T18:55:45.520Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02892149", "title": "Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia", "Dialysis-Dependent Chronic Kidney Disease" ], "interventions": [ { "name": "Vadadustat", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akebia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3554, "start_date": "2016-08", "completion_date": "2020-03-30", "has_results": true, "last_update_posted_date": "2022-06-28", "last_synced_at": "2026-09-25T18:55:45.520Z", "location_count": 127, "location_summary": "Huntsville, Alabama • Mesa, Arizona • Pine Bluff, Arkansas + 95 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02892149" }, { "nct_id": "NCT00334737", "title": "Darbepoetin Administration to Preterm Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infant, Newborn" ], "interventions": [ { "name": "Darbepoetin Alfa Injection", "type": "DRUG" }, { "name": "erythropoietin alfa injection", "type": "DRUG" }, { "name": "sham injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Hour", "maximum_age": "49 Hours", "sex": "ALL", "summary": "1 Hour to 49 Hours" }, "enrollment_count": 102, "start_date": "2006-06", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2019-02-04", "last_synced_at": "2026-09-25T18:55:45.520Z", "location_count": 3, "location_summary": "Denver, Colorado • Ogden, Utah • Salt Lake City, Utah", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Ogden", "state": "Utah" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00334737" }, { "nct_id": "NCT00858364", "title": "Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer", "Anemia", "Cancer", "Lung Cancer" ], "interventions": [ { "name": "Darbepoetin alfa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2549, "start_date": "2009-07-17", "completion_date": "2017-06-07", "has_results": true, "last_update_posted_date": "2022-11-30", "last_synced_at": "2026-09-25T18:55:45.520Z", "location_count": 277, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Anchorage, Alaska + 243 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00858364" }, { "nct_id": "NCT03029208", "title": "Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anaemia" ], "interventions": [ { "name": "Daprodustat", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" }, { "name": "Iron therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 312, "start_date": "2017-05-11", "completion_date": "2020-09-24", "has_results": true, "last_update_posted_date": "2021-10-20", "last_synced_at": "2026-09-25T18:55:45.520Z", "location_count": 36, "location_summary": "Anaheim, California • Cerritos, California • Escondido, California + 31 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "La Palma", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03029208" }, { "nct_id": "NCT00520468", "title": "Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Erythropoietin", "type": "DRUG" }, { "name": "Cyclosporin A", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 15, "start_date": "2004-06", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2012-08-07", "last_synced_at": "2026-09-25T18:55:45.520Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00520468" }, { "nct_id": "NCT00146562", "title": "Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Stage I Breast Cancer", "Stage II Breast Cancer" ], "interventions": [ { "name": "Darbepoetin Alfa", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harold J. Burstein, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2003-07", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2023-08-02", "last_synced_at": "2026-09-25T18:55:45.520Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Lowell, Massachusetts • Peabody, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Lowell", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00146562" }, { "nct_id": "NCT01065870", "title": "Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Pancreatic Cancer Stage II", "Pancreatic Cancer Stage III" ], "interventions": [ { "name": "Neoadjuvant gemcitabine, capecitabine, and docetaxel", "type": "DRUG" }, { "name": "Gemcitabine, capecitabine, docetaxel followed by radiotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2009-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-29", "last_synced_at": "2026-09-25T18:55:45.520Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01065870" }, { "nct_id": "NCT02273726", "title": "Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "CKD Anemia in Stable Dialysis Patients" ], "interventions": [ { "name": "Epoetin Alfa", "type": "DRUG" }, { "name": "Roxadustat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyntra Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 741, "start_date": "2015-01-15", "completion_date": "2018-09-19", "has_results": true, "last_update_posted_date": "2021-10-29", "last_synced_at": "2026-09-25T18:55:45.520Z", "location_count": 74, "location_summary": "Phoenix, Arizona • Pine Bluff, Arkansas • Chula Vista, California + 58 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Chula Vista", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02273726" }, { "nct_id": "NCT00230321", "title": "A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Blood Cancer", "Myelodysplastic Syndromes", "Myelodysplastic Syndromes (MDS)" ], "interventions": [ { "name": "Darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Peter L Greenberg", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2002-02", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2013-02-04", "last_synced_at": "2026-09-25T18:55:45.520Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00230321" }, { "nct_id": "NCT00058422", "title": "Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "darbepoetin alfa", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "indium In 111 ibritumomab tiuxetan", "type": "RADIATION" }, { "name": "yttrium Y 90 ibritumomab tiuxetan", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "60 Years to 120 Years" }, "enrollment_count": 65, "start_date": "2003-02-10", "completion_date": "2019-11-14", "has_results": true, "last_update_posted_date": "2020-11-12", "last_synced_at": "2026-09-25T18:55:45.520Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00058422" } ] }